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Abstract
Objective The aim of this paper was to review and com-
pare HIV vaccine cost-effectiveness analyses and describe
the effects of uncertainty in model, methodology, and
parameterization.
Methods We systematically searched MEDLINE (1985
through May 2016), EMBASE, the Tufts Cost-Effective-
ness Analysis (CEA) Registry, and the reference lists of
articles following Cochrane and Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines. Eligibility criteria included peer-reviewed
manuscripts with economic models estimating the cost-
effectiveness of preventive HIV vaccines. Two reviewers
independently assessed study quality and extracted data on
model assumptions, characteristics, input parameters, and
outcomes.
Results The search yielded 71 studies, 11 of which met the
inclusion criteria. Populations included low-income
(n = 7), middle-income (n = 4), and high-income coun-
tries (n = 2). Model structure varied, including decision
tree (n = 1), Markov (n = 5), compartmental (n = 4), and
microsimulation (n = 1). Most studies measured outcomes
in quality-adjusted life-years (QALYs) gained (n = 6),
whereas others used unadjusted (n = 3) or disability-ad-
justed life-years (n = 2). The range of HIV vaccine costs
were $US1.54–75 in low-income countries, $US55–100 in
middle-income countries, and $US500–1000 in the USA.
Base-case incremental cost-effectiveness ratios (ICERs)
ranged from dominant (cost offsetting) to $US91,000 per
QALY gained.
Conclusion Most models predicted HIV vaccines would be
cost-effective. Model assumptions about vaccine price,
HIV treatment costs, epidemic context, and willingness to
pay influenced results more consistently than did assump-
tions on HIV transmission dynamics.
Key Points for Decision Makers
Most economic models predict HIV vaccines will be
cost-effective.
Static and dynamic HIV transmission modeling
methods found similar results.
Vaccine cost-effectiveness will likely depend on
HIV prevalence, durability of protection, and price
of regimen and boosts.
1 Introduction
The search for an HIV vaccine began over 3 decades ago
and had a breakthrough in 2009 [1]. A phase III HIV
vaccine trial in Thailand (RV144) found HIV vaccine
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efficacy (VE) of 31.2% over 3 years [2, 3]. Though the
durability of protection was low, vaccine boosting
4–5 years later restored the immune response to HIV [4].
An efficacy trial in South Africa (HVTN 702) is ongoing to
confirm the canarypox-based vaccine ALVAC-HIV and
bivalent gp120 protein subunit boost evidence with funding
from the National Institute of Allergy and Infectious Dis-
eases (NIAID) and other members of the Pox-Protein
Public–Private Partnership (P5). The vaccine product was
modified to match the predominant HIV strain in Africa
and includes the potentially more immunogenic adjuvant
MF59. With an added vaccine dose at 12 months, totaling
five injections, the regimen is expected to increase the
magnitude and duration of vaccine-elicited immune
responses [5]. Walensky et al. [6] previously defined sev-
eral characteristics of a ‘good enough’ therapeutic vaccine
for HIV-infected individuals to replace antiretroviral ther-
apy (ART) in the USA, but the characteristics of a clini-
cally and economically viable preventative HIV vaccine
have not been defined. When licensed, HIV vaccines may
complement or compete with other HIV-prevention inter-
ventions such as voluntary male circumcision, treatment as
prevention, and now pre-exposure prophylaxis (PrEP).
Decision makers now balance investment in the continued
development of HIV vaccines and confirmatory trials in
Southern Africa with other opportunities to incrementally
improve combination HIV-prevention effectiveness [7].
Over the long term, many view the development of a safe
and effective HIV vaccine as the only hope to completely
eradicate AIDS [8, 9]. This article aims to review existing
studies of HIV vaccine cost-effectiveness to identify
characteristics of HIV vaccines that may be essential to the
value and viability of vaccination.
1.1 Rationale
Cost-effectiveness research guides efficient spending of
limited healthcare resources and also contributes to
research and development (R&D) decision making and
prioritization of early-phase products through a clinical
trial pipeline. Multifaceted decision making and value
assessment of vaccines in development often draw upon
economic modeling predictions [10]. Many complex
mathematical models have simulated the potential impact
of HIV vaccines on transmission of the virus, but few have
included costs or measured health outcomes for compar-
ison with other healthcare investments. Unlike models of
chronic diseases, sexually transmitted infections often
require the addition of transmission dynamics to capture
the indirect effect, or positive externality, of herd immu-
nity. Brisson and Edmunds [11] previously showed the
impacts of modeling, methodological, and parameter
uncertainty on economic analyses of varicella vaccination
and emphasized how choices in model development can
lead to disparate results. Because few cost-effectiveness
studies exist in this area, we aimed to assess methodolog-
ical differences between studies that may influence impli-
cations of value from a vaccine. Comparing detailed
characteristics of the small number of existing studies
allows us to identify key methods or population charac-
teristics that strongly influence results. As vaccine devel-
opment progresses, it will be of key importance to assess
both clinical and economic feasibility of widespread vac-
cination campaigns. In this review, we aimed to identify
key methodological drivers of, and variability in, the
potential cost-effectiveness of an HIV vaccine. Our aim for
this work is to help facilitate an informed and successful
roll out of a future vaccine. While the cost-effectiveness of
PrEP for HIV prevention has been systematically reviewed
previously [12, 13], this is the first review of HIV vaccine
cost-effectiveness.
1.2 Objectives
The main objective of this review was to identify and
summarize HIV vaccine cost-utility analyses to understand
conditions where vaccination has the potential to be cost-
effective or cost saving. On the basis of economic models
identified through a systematic review, the secondary
objective was to evaluate and compare modeling,
methodological, and parameter uncertainty based on
guidelines and best practices for dynamic transmission
modeling. The range in approaches to address uncertainty
provided a case study for methodological comparison of
economic modeling in infectious diseases. This paper was
targeted at clinical trial scientists and funders to guide
identification of characteristics of an HIV vaccine that
would be most critical to the economic viability of the
vaccine.
2 Methods
We conducted a systematic review following methods from
the Cochrane Collaboration and the Agency for Healthcare
Research and Quality (AHRQ) guides for systematic
reviews [14, 15]. Content aligns with the Preferred
Reporting Items for Systematic Reviews and Meta-Anal-
yses (PRISMA) statement for transparent reporting of
systematic reviews [16].
2.1 Eligibility Criteria
Eligible articles were published in peer-reviewed journal
articles from 1985 to May 2016 in the English language
and included an analysis that predicted the economic
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impact of an HIV vaccine. Eligibility was limited to studies
estimating incremental costs and health outcomes mea-
sured in units comparable across diseases, including qual-
ity-adjusted life-years (QALYs) gained, disability-adjusted
life-years (DALYs) averted, or life-years (LYs). For ease
of comparability, the review was limited to preventive
vaccines of uninfected individuals and excluded therapeu-
tic vaccines for existing HIV patients. Budget-impact
analyses, HIV vaccine acceptability, and willingness-to-
participate studies were excluded, as were editorial com-
mentaries, conference abstracts, and book chapters.
2.2 Search Methods and Sources
Two reviewers independently searched databases using a
pre-specified protocol. The PubMed and MEDLINE search
included ((‘‘cost benefit analysis’’ [medical subject heading
(MeSH) terms] OR ‘‘cost-effectiveness’’ [all fields]) AND
(‘‘aids vaccines’’[MeSH] OR ‘‘hiv vaccine’’[all fields])).
EMBASE was searched for the keywords ‘cost-effective-
ness analysis’ AND (‘aids vaccine’ OR ‘hiv vaccine’). The
Tufts Center for the Evaluation of Value and Risk in Health
(CVER) Cost-Effectiveness Analysis (CEA) Registry was
searched for ‘‘HIV vaccine’’ and ‘‘AIDS vaccine.’’ Authors
screened the reference lists of relevant articles for addi-
tional studies not identified in the database searches.
2.3 Study Selection
Records identified through database and registry searches
were merged into the reference manager Mendeley and
duplicates removed. Two reviewers (author BA and
acknowledged contributor NV) independently searched and
screened the titles and abstracts of all identified records,
excluded those not meeting the defined criteria, and
assessed the full text of all remaining articles for eligibility.
Disagreements or uncertainty in eligibility were discussed
and resolved with input from a third reviewer (BD).
2.4 Data Extraction
Two reviewers (BA and DD) extracted model character-
istics, methods, parameter values, and results from identi-
fied manuscripts by populating a standardized table. The
following data elements were sought from each manuscript
and its supplemental materials: population studied (region,
demographics, local HIV prevalence and incidence), HIV
vaccine characteristics (regimen, efficacy, durability, and
price), model features (name, structure, outcome measure,
perspective, discount rates, time horizon, years modeled,
transmission dynamics, and assumptions), and results (in-
cremental cost-effectiveness ratio [ICER], willingness-to-
pay [WTP] or cost-effectiveness threshold, interpretation
of cost-effectiveness results, sensitivity-analysis methods,
and findings of sensitivity analyses). ICER was defined as
the marginal cost per marginal health gained with the
following equation:
ICER ¼ D Costs
D Effectiveness
:
To compare the magnitude of cost-effectiveness in
relation to the corresponding country’s gross domestic
product (GDP) and compare results across studies, we
present raw study-reported ICERs and ‘standardized’ cost-
effectiveness. Standardized cost-effectiveness was defined
as the ratio of ICER to the study-defined WTP threshold,
where standardized ICER/WTP values \1 are consistent
with the reviewed study author’s interpretation as ‘cost-
effective,’ values [1 are ‘unlikely cost-effective,’ and
negative values are likely cost saving for the case of
vaccines.
2.5 Critical Appraisal
The quality of model reporting was evaluated using the
Consolidated Health Economic Evaluation Reporting Stan-
dards (CHEERS) checklist [17]. Our comparisons of model
uncertainty and results were guided by recommendations
from the US Panel on Cost-Effectiveness in Health and
Medicine [38, 39], the World Health Organization (WHO)
Guide to Cost-Effectiveness [18], and Briggs [19, 42].
Reviewers assessed the frequency best practices were used as
recommended by the International Society for Pharma-
coeconomics and Outcomes Research (ISPOR)–Society for
Medical Decision Making (SMDM) Modeling Good
Research Practices Task Force on dynamic transmission
modeling [20]. The terms ‘cost-effectiveness’ and ‘cost-util-
ity’ are used interchangeably through this review, aligning
with language from the selected articles while recognizing
that cost-utility is a sub-type of cost-effectiveness where the
outcome is in units such as QALYs or DALYs.
Though types of model structures are not mutually
exclusive, for simplicity the studies were categorized into
general types. Decision trees include a series of chance
nodes with the probability each outcome will occur using a
series of branches. Markov and semi-Markov models
describe transitions through health states of a cohort of
patients over time. Compartmental models use a system of
differential equations to describe a fluctuating population
in health states over time. Finally, the microsimulation
model structure describes individual agents with defined
characteristics as part of a whole fluctuating population
over time. Technical strengths and limitations of dynamic
transmission assumptions were interpreted with infectious
disease mathematical modeling texts by Keeling and
Rohani [21] and Vynnycky and White [22].
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3 Results
3.1 Selection of Studies
Of the 71 unique records identified from searches, the
reviewers assessed 24 full-text articles for eligibility and
excluded 13 articles during full-text assessment (Fig. 1).
Table 1 summarizes the 11 economic modeling studies
meeting the eligibility criteria for inclusion in this review
[23–33].
3.2 Characteristics of Studies
Methods, population studied, vaccine assumptions, and
results are presented in Table 2 and in Fig. S1 in the
Electronic Supplementary Material (ESM). The regions of
interest included low-income (n = 7), middle-income
(n = 4), and high-income countries (n = 2). Two studies
using the Goals model (SPECTRUM software package,
Avenir Health) included 26 countries in Africa, Asia, Latin
America, and Eastern Europe [30, 33]. All models reported
parameterization using local epidemiological data on HIV.
Economic perspectives included the payer (n = 1), gov-
ernment (n = 1), health system (n = 5), and societal or
limited societal (n = 4). All studies included a reference
group scenario following regional HIV-prevention prac-
tices and the standard of care in HIV treatment. Stover
et al. [33] also compared vaccines against scale-up of
treatment as prevention (TasP) and explored combining
vaccines with TasP and PrEP. The number of studies
following each ISPOR–SMDM dynamic transmission task
force best practice recommendation is provided in Table S1
in the ESM. Though best practice suggests varying the time
horizon in dynamic transmission models, none of the
studies varied the time horizon in sensitivity analyses.
The most frequent measure of intervention impact was
incremental QALYs gained (n = 6). Two studies estimated
DALYs averted, and the remaining three compared dif-
ferences in total LYs. Bos et al. [23] incorporated the cost
of counseling for an infant’s mother with the vaccination
series that may parallel the future of vaccine-induced
seropositive (VISP) counseling. No studies included a
transient or long-term disutility associated with
vaccination.
3.3 Model Structure
The earliest study in 2001 evaluated HIV vaccination with
a simple decision tree. Two Markov models were published
5 years later and then followed by the first dynamic
transmission cost-effectiveness model in 2009. Since 2009,
four of the eight HIV vaccine economic models used dif-
ferential equations to simulate HIV transmission (Table 2).
The Markov, compartmental, and microsimulation-based
models stratified the risk of HIV infection by age, sex, and/
or risk group.
In contrast to the closed-cohort populations in the
decision tree and Markov models, the compartmental and
microsimulation models allowed for fluctuating popula-
tions, with susceptible individuals entering the population
at their sexual debut. Models by Leelahavarong et al. [29]
Fig. 1 Flow of information
through the different phases of
the HIV vaccine cost-
effectiveness model systematic




4 B. Adamson et al.
and Moodley et al. [31, 32] tried to overcome the memory-
less nature inherent in Markov models by using tunnel
states. Alternatively, a microsimulation [28] explicitly
modeled sexual partnerships while accounting for hetero-
geneity between people. This structure makes it easier to
model preferential/targeted vaccination and revaccination
and was designed to reflect individual preferences for
participation in healthcare and prevention programs.
Studies modeled HIV transmission as static (n = 6) or
dynamic (n = 5). In the static models, including the deci-
sion tree and Markov models, the probability of HIV
transmission at each time step remained constant over time.
In the dynamic models, including ordinary differential
equation and agent-based microsimulation models, infec-
tions depend on the number of infected and uninfected
individuals at each time point as well as on the sexual
mixing between different groups. As a result, dynamic
models captured not only the direct effects of the interven-
tion on the susceptibility of the vaccinated individuals but
also the indirect effects on HIV transmission by accounting
for the decreasing exposure to HIV over time (herd immu-
nity). The static models did not address sexual mixing. The
hypothesis of risk compensation, assuming that individuals
exhibit riskier sexual behavior when they perceive them-
selves as protected from HIV, was explored in four of the
models [27, 28, 30, 33]. Hontelez et al. [28] concluded that
this potential change in risk following vaccination could
nullify the epidemic impact in South Africa.
3.4 Vaccine Effectiveness
The average of 3-year HIV VE values across all studies
was 51.3% (Fig. 2). Sensitivity analyses included a range
of efficacy from 10 to 90%. Though uncertainty in HIV VE
decreased following the Thai trial results in 2009, the
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Structure Decision tree Markov Markov Compartmental Compartmental Micro-simulation Semi-Markov Compartmental Compartmental 
Semi-
Markov Semi-Markov 
Outcome DALY LY LY and DALY QALY QALY LY ~ DALY QALY QALY QALY QALY YPG 
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The parameters and ICERs represent the base-case or average values in each analysis and do not reflect ranges evaluated in sensitivity analyses.
Blue shading: 2011 study is an update to the 2009 model by same author. Pale grey shading: Stover et al. [33] and Harmon et al. [30] studies both
used the Goals model with Spectrum software, so parameters are similar. Dark grey shading: two models in 1 calendar year by the same first
author with similar parameters
a These studies did not explicitly state their economic perspective, and the perspective listed here was deduced by review authors based on
context. Two values are listed for several Harmon parameters to reflect the separate low-income country (LIC) and middle-income country (MIC)
analyses
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average of estimates from models before 2009
(VE = 49%; n = 0.4) did not greatly differ from the
average of the estimates after 2009 (VE = 52%; n = 7).
Eight of the 11 studies assumed that VE protection
remained constant over time, whereas three studies mod-
eled efficacy declining over time since immunization. All
studies published after 2009 included boosts from re-vac-
cination to ensure continuity of protection, following the
results from the Thai trial [2]. Two studies from a 2011
theme issue of Vaccine (Nagelkerke et al. [34] and Long
and Owens [27]) modeled VE decaying over time with a
functional form of VE = 0.78 9 exp-0.06t, where t = time
since vaccination in months.
3.5 Costs
All studies discounted total costs by 3% annually, and most
described ranging this rate in the sensitivity analysis.
Table 2 Target population, modeling methods, vaccine characteris-




South Africa 7 64
Thailand 4 36




Single country 7 64




Health system 5 45
Limited societal 4 36
Defined willingness to pay 9 82
Discounted costs, 3% 11 100
Discounted outcomes, 3% 8 73
Modeling methods
Model type
Decision tree 1 9
Markov or semi-Markov 5 45
Compartmental, ODE 4 36
Agent-based 1 9






10-year horizon 3 27
20- to 43-year horizon 3 27




9–15 years 4 36
[15 years 6 55




Lifetime protection 3 27
Waning protection 8 73








Risk compensation 5 45
Results and conclusions
ICERs (per QALY, DALY, or LY)





Unlikely cost-effective 2 18
No interpretation 1 9
DALYs disability-adjusted life-years, ICER incremental cost-effec-
tiveness ratio, LYs life-years, ODE ordinary differential equations,
QALYs quality-adjusted life-years
a The Goals model includes 24 countries and assumed a price of
$US20 for low-income countries and $US55 for middle-income
countries
Fig. 2 Assumed HIV vaccine efficacy and price per series (log scale)
across the 11 studies reviewed
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Health outcomes were discounted at 3% in eight (73%)
analyses [23, 25–29, 31, 32]. In the year of this review,
HIV vaccines are not licensed and the market price has not
been set. Modelers assumed the average cost of a vaccine
series was $US1.54–75 in low-income countries,
$US55–100 in middle-income countries, and
$US500–1000 in the USA (Fig. 2). There was no observ-
able trend in pricing assumptions by efficacy across studies
(Fig. 4c). The cost of HIV care and treatment varied widely
between studies according to local healthcare costs and
contributed greatly to differences in cost-effectiveness
results. No studies included future research and develop-
ment costs for the HIV vaccine leading to licensure.
3.6 Cost-Effectiveness
Base-case ICERs ranged from dominant (cost offsets) to
$US91,000 per QALY gained (Table 1; Fig. 3a). The
Goals model studies [30, 33] found similar ICER esti-
mates, ranging from approximately $US1000 to
$US11,000 per QALY across 24 low- and middle-in-
come countries [30, 33]. Nine of the 11 studies pre-
specified a local WTP or cost-effectiveness threshold to
interpret results. Base-case vaccination scenarios were
not cost-effective in three of the 11 models, including
one low-, one middle-, and one high-income country
(Fig. 3b). Stover et al. [33] did not explicitly interpret
the cost-effectiveness of their results, so we inferred the
cost-effectiveness threshold from the supporting infor-
mation from Harmon et al. [30]. In the rest of the
studies, three projected that vaccinations in their base-
case scenarios were cost-effective, three were highly
cost-effective, and two were cost-saving. Several mod-
els used sensitivity analyses to identify target popula-
tions for cost-saving vaccination. All modelers agreed
that targeting groups with the highest HIV incidence
improves cost-effectiveness. As expected, WTP-stan-
dardized ICERs increased as price increased (Fig. 4a).
There was no clear trend in association between vaccine
efficacy and cost-effectiveness across studies (Fig. 4b).
All studies evaluated parameter uncertainty based on
one-way sensitivity analyses. Five used scenario analyses
to understand uncertainty by changing several parameters
at one time to observe the change in cost-effectiveness.
Both models by Moodley et al. [31, 32] in 2016 performed
multivariate sensitivity analysis using 1000 Monte Carlo
simulations based on random draws from each variable
distribution to evaluate the combined effect of parameter
uncertainty on the study results. Appropriate to the dif-
fering structural form, Hontelez et al. [28] correspondingly
Fig. 3 Cost-effectiveness studies of HIV vaccines. a Incremental
cost-effectiveness ratio results from the base case of each study
reviewed; error bars represent lower and upper ranges from the
sensitivity analysis; b same as a with ICER standardized to
willingness-to-pay threshold specified by study (see Table 1). The
ICER uncertainty from Hontelez et al. [28] is reported in one
direction as a result of the threshold analysis method to set the vaccine
price, resulting in an ICER equal to the country-specific willingness to
pay. Two authors are included twice to reflect different results from
multiple publications (Long [26, 27] and Moodley [31, 32]), while
another presented results for two populations within one publication
(Harmon et al. [30]). Amirfar et al. [24] and Stover et al. [33] did not
explicitly state cost-effectiveness thresholds. The threshold from
Harmon et al. [30] was applied to the Stover et al. [33] study as both
model the same 26 countries. Standardized ICER = ICER/WTP.
ICER incremental cost-effectiveness ratio, WTP willingness to pay
per health unit gained
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characterized combined uncertainty with simulation of
1000 individuals and scenarios. Three of the 11 studies
reported model validation of epidemic predictions using
historical HIV surveillance data. Scenario analyses that
focused on men who have sex with men and injection drug
users were found to be more cost-effective than vaccination
of the general population. Several studies discussed how a
targeted immunization strategy for high-risk sub-popula-
tions could result in cost savings for a health system. The
microsimulation structure captured patient heterogeneity
and sexual mixing more specifically and intentionally than
the other economic models and reached very similar
conclusions.
4 Discussion
This systematic review aimed to identify HIV vaccine
characteristics and vaccination conditions that may be
critical for an HIV vaccine to be cost-effective and valu-
able. The comparison of the published modeling studies
suggested HIV vaccines with an average of 50% efficacy
waning over 3 years and supplemented by boosting every
few years may be a realistic profile for a ‘good enough’
vaccine to make a large impact on the HIV epidemic. As
shown in this collection of economic models, a moderately
effective vaccine could be cost-effective in developed and
Fig. 4 Vaccine price and efficacy relationship with standardized
cost-effectiveness (ICER/WTP) stratified by country income level.
The ICER uncertainty from Hontelez et al. [28] is reported in one
direction as a result of the threshold analysis method to set the vaccine
price, resulting in an ICER equal to the country-specific willingness to
pay. Three authors are included twice to reflect different results from
multiple publications (Long [26, 27] and Moodley [31, 32]) and
analysis of two populations in one publication (Harmon et al. [30]).
Amirfar et al. [24] and Stover et al. [33] did not explicitly state cost-
effectiveness thresholds. The threshold from Harmon et al. [30] was
applied to the Stover et al. [33] study as both model the same 26
countries. Standardized ICER = ICER/WTP. ICER incremental cost-
effectiveness ratio. WTP willingness to pay per health unit gained
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developing countries. The potential cost-effectiveness of
vaccination was strongly linked to the HIV burden in each
population, but a formal meta-analysis was not conducted
because of the heterogeneity between studies. Two studies
[27, 29] that predicted HIV vaccines were unlikely to be
cost-effective had in common a lower-incidence general
population as the target for vaccination. Vaccines targeted
to individuals at greater risk of HIV infection will improve
cost-effectiveness within the health system, and models did
not predict that sexual mixing patterns would dilute the
effects of targeted vaccination.
The potential cost-effectiveness of HIV vaccines
depended on price and average efficacy. As the price of an
HIV vaccine series increased in sensitivity analyses, there
reached a point where vaccination would no longer be cost-
effective. This threshold for vaccine price depended on
each country’s GDP per capita. Several studies explored
the components contributing towards average efficacy,
such as the rate of decay in immunogenicity, the corre-
sponding durability of protection, the proportion of people
who respond, and the frequency of boosting. Our qualita-
tive review indicated a moderately effective vaccine profile
with poor durability and frequent boosting could have
greater impact on the HIV epidemic than a single vacci-
nation series with improved durability. This suggests future
studies in non-human primates and humans should care-
fully evaluate the change in breadth and depth of
immunological response following repeated boosting every
2–5 years.
While we did not find any infectious disease modeling
method reviewed to be more valid than others, the structure
and assumptions should be carefully selected based on the
question of interest and data available. As HIV-prevention
and treatment guidelines change dramatically over time,
future economic models in HIV prevention should clearly
define the reference standard of care and consider including
PrEP as a component in the reference for comparison. This
need for standardized components, methods, and perspec-
tives to enhance comparability among studies is further
supported by a new report from the Second Panel on Cost-
Effectiveness in Health and Medicine [38, 39].
The 11 studies published between 2001 and 2016
exemplified a diverse range of model structure choices,
economic methods, and population-specific parameter
values. Almost half (n = 5) of the studies did not clearly
state or define an economic perspective. Impact measured
in unadjusted LYs gained did not consider quality of life
and may have underestimated the total benefit from vac-
cination [24, 28, 32]. Fundamental to the epidemiology of
infectious diseases, one expects the average age at diag-
nosis to increase as HIV prevalence decreases and exposure
to infection is delayed. For example, two infected lives
ending at 60 years from death unrelated to HIV have the
same value in LYs as if HIV infection occurred at 30 or
55 years of age. Alternatively, studies estimating QALYs
or DALYs capture a difference in total health based on the
preference for more healthy years lived before HIV
infection. A surprising majority of studies measured impact
in QALYs when considering a perception that DALYs are
used more often than QALYs for developing countries. We
assume the interpretation of QALYs gained versus DALYs
averted is the same, though the potential for differences has
been discussed elsewhere [36, 37].
If most of the health gains from a vaccine were accumu-
lated late in the time horizon, then models discounting costs
only [24, 30, 33] would be more likely to produce results that
are cost-effective than studies that discount both costs and
QALYs. Reports including plots of cumulative health out-
comes, changes in HIV incidence over time, and sensitivity
analyses with undiscounted costs and outcomes most effec-
tively communicated the timing of initial vaccine invest-
ment, accrual of HIV care cost savings, and the time to
capture significant population health gains.
Despite professional society best practice recommen-
dations for dynamic transmission modeling [20], no studies
presented results using more than one time horizon (sup-
plementary materials (ESM)). Most studies justified their
choice of model structure and conducted some sensitivity
analyses of structural assumptions. A minimal modeling
movement advocates that development of models should
be as simplistic as possible to answer one question of
interest [40]. The articles reviewed highlight that a benefit
of simple models is the ease of interpretation. Evaluating
and balancing the importance of clinical and epidemio-
logical assumptions is vital for readers to assess the face
validity of economic models. Each modeling choice has
trade-offs, and while a behavioral HIV-prevention inter-
vention may require model complexity of heterogeneous
sexual networks with concordancy and preferential mixing,
researchers of different interventions not affecting these
dynamics may value the benefits of simplicity more than
potential incremental validity gained.
We identified a diverse variety of modeling structures
and assumptions applied to this infectious disease. Deci-
sion trees and Markov models are often developed to
evaluate the cost-effectiveness of pharmaceuticals, though
in this case only the compartmental and microsimulation
models captured the indirect effects of vaccination. Fun-
damental features for HIV vaccines included local HIV
incidence data, a clearly defined population, assumption of
efficacy and its waning, the local WTP for health gains,
and—importantly—the vaccine price. Like the results from
Brisson and Edmunds [11], our qualitative review high-
lights that choices in (1) the model type and structure, (2)
economic methods, and (3) parameter values all introduced
uncertainty for decision makers.
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This qualitative review had several limitations. The
uncertainty in future HIV vaccine characteristics and small
number of studies available posed a challenge in drawing
definitive conclusions based on this review. As the epi-
demic context and economic conditions varied greatly
between study populations, a meta-analysis was not pos-
sible. Over the years 2001–2016, when the 11 studies were
published, the technology, access, and standards for HIV
testing and treatment changed over time and by country.
However, all the studies published after 2009 modeled
similar regimens of multi-dose vaccination with waning
efficacy over time that correspond to the vaccine candi-
dates currently tested in clinical studies. Reference groups
for comparison differ and limit the ability to compare
across studies. We assumed methodological differences
measuring health outcomes in units of QALYs, DALYs,
and LYs did not change overall findings or ICER inter-
pretation. There was potential for incomplete retrieval of
published research manuscripts, and publication bias may
have prevented analyses with inconclusive findings from
being submitted to or accepted by journals. Well-crafted
economic models of HIV vaccines presented in book
chapters, conference presentations, or languages other than
English were potentially missed.
5 Conclusion
The 11 published studies found HIV vaccines to be cost-
effective under certain conditions. HIV vaccine cost-ef-
fectiveness depended most on efficacy, price, and HIV
incidence in the target population. Country-specific cost
inputs and WTP thresholds may explain differences in
cost-effectiveness. The studies provided evidence that
immunization with a modestly effective HIV vaccine is
likely an efficient use of resources in the USA, Thailand,
and several sub-Saharan African countries, though decision
makers must balance the studies’ findings with acknowl-
edgement of great uncertainty. The review suggests
regional HIV epidemiology and assumed WTP thresholds
were more influential on study findings than differences
from a methodological choice of static or dynamic HIV
transmission. The broad disciplinary range among authors
affirms the need for interdisciplinary collaboration between
health economists, epidemiologists, clinicians, infectious
disease mathematical modelers, biostatisticians, and clini-
cal trial scientists to develop valid and meaningful results.
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